Department of Urology, The Oncology Institute "Prof Dr. Ion Chiricuta", 400015 Cluj-Napoca, Romania.
Department of Urology, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Medicina (Kaunas). 2020 Feb 24;56(2):94. doi: 10.3390/medicina56020094.
Prostate cancer is one of the most encountered cancer diseases in men worldwide and in consequence it requires the improvement of therapeutic strategies. For the clinical diagnosis, the standard approach is represented by solid biopsy. From a surgical point of view, this technique represents an invasive procedure that may imply several postoperative complications. To overcome these impediments, many trends are focusing on developing liquid biopsy assays and on implementing them in clinical practice. Liquid samples (blood, urine) are rich in analytes, especially in transcriptomic information provided by genetic markers. Additionally, molecular characterization regarding microRNAs content reveals outstanding prospects in understanding cancer progression mechanisms. Moreover, these analytes have great potential for prostate cancer early detection, more accurate prostate cancer staging and also for decision making respecting therapy schemes. However, there are still questionable topics and more research is needed to standardize liquid biopsy-based techniques.
前列腺癌是全球男性最常见的癌症之一,因此需要改进治疗策略。在临床诊断中,标准方法是进行实体组织活检。从手术角度来看,这种技术是一种侵入性的程序,可能会导致多种术后并发症。为了克服这些障碍,许多趋势都集中在开发液体活检分析上,并将其应用于临床实践中。液体样本(血液、尿液)中富含分析物,特别是遗传标记提供的转录组信息。此外,关于 microRNAs 含量的分子特征分析在理解癌症进展机制方面显示出了巨大的前景。此外,这些分析物在前列腺癌早期检测、更准确的前列腺癌分期以及治疗方案决策方面具有很大的潜力。然而,仍有一些值得商榷的问题,需要进一步的研究来标准化基于液体活检的技术。